Janney Montgomery Scott LLC increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,602 shares of the medical equipment provider’s stock after buying an additional 929 shares during the period. Janney Montgomery Scott LLC’s holdings in Boston Scientific Corporation were worth $1,486,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in BSX. BlackRock Inc. raised its position in Boston Scientific Corporation by 2,181.6% in the first quarter. BlackRock Inc. now owns 95,744,545 shares of the medical equipment provider’s stock worth $2,381,169,000 after buying an additional 91,548,235 shares during the period. FMR LLC raised its position in Boston Scientific Corporation by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after buying an additional 13,105,596 shares during the period. MARSHALL WACE ASIA Ltd bought a new position in Boston Scientific Corporation during the first quarter worth $149,859,000. Marshall Wace North America L.P. bought a new position in Boston Scientific Corporation during the first quarter worth $149,859,000. Finally, Vanguard Group Inc. raised its position in Boston Scientific Corporation by 4.0% in the first quarter. Vanguard Group Inc. now owns 91,134,744 shares of the medical equipment provider’s stock worth $2,266,521,000 after buying an additional 3,503,965 shares during the period. Institutional investors and hedge funds own 92.08% of the company’s stock.

Shares of Boston Scientific Corporation (BSX) opened at 26.57 on Thursday. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.51. The stock has a market capitalization of $36.41 billion, a P/E ratio of 47.53 and a beta of 1.09. The stock’s 50 day moving average price is $27.43 and its 200-day moving average price is $26.02.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.27 earnings per share. Equities research analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/boston-scientific-corporation-bsx-position-boosted-by-janney-montgomery-scott-llc/1467964.html.

A number of equities research analysts have commented on BSX shares. Needham & Company LLC raised their price objective on Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 22nd. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. Goldman Sachs Group, Inc. (The) started coverage on Boston Scientific Corporation in a research report on Tuesday, May 16th. They set a “neutral” rating and a $28.00 price objective for the company. Zacks Investment Research lowered Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Guggenheim restated a “buy” rating on shares of Boston Scientific Corporation in a research report on Wednesday, April 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $30.06.

In other Boston Scientific Corporation news, EVP Kevin J. Ballinger sold 28,864 shares of the company’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $26.14, for a total value of $754,504.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Daniel J. Brennan sold 92,158 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total value of $2,532,501.84. Following the completion of the sale, the chief financial officer now owns 235,421 shares in the company, valued at approximately $6,469,369.08. The disclosure for this sale can be found here. Insiders sold 236,489 shares of company stock worth $6,440,888 in the last 90 days. Corporate insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.